Shots:
- Rigel has entered into an exclusive, global license agreement with Arvinas & Pfizer to develop, manufacture & commercialize FDA-approved Veppanu (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
- As per the deal, Rigel will pay Arvinas & Pfizer $70M upfront, $15M in upon completion of transition activities, & ~$320M in milestones plus tiered royalties ranging from mid-teens to mid-twenties, while contributing up to $40M toward ongoing development activities over the next 4yrs.
- Rigel will lead the US launch & commercialization of Veppanu while holding global sublicensing rights for ex-US development & commercialization, with Arvinas & Pfizer eligible to receive a share of ex-US sublicensing revenues
Ref: PRnewswire | Image: Rigel, Pfizer & Arvinas | Press Release
Related News: Arvinas and Pfizer Report the US FDA Approval of Veppanu (Vepdegestrant) for ESR1-Mutated Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
